In a recent randomized trial, electromotive intravesical administration of mitomycin before transurethral resection was shown to be effective in the prevention of bladder cancer recurrence. Although this treatment seems to be promising, one question remains: can these results be reproduced by other research groups? If this is the case, it could become a new standard.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis
Tumor Biology Open Access 05 January 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kalsi, J., Harland, S. J. & Feneley, M. R. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma. Expert Opin. Drug. Deliv. 5, 137–45 (2008).
Brausi, M. et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51, 506–509 (1998).
Riedl, C. R., Knoll, M., Plas, E. & Pflüger, H. Intravesical electromotive drug administration technique: preliminary results and side effects. J. Urol. 159, 1851–1856 (1998).
Di Stasi, S. M. et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170, 777–782 (2003).
Di Stasi, S. M. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7, 43–51 (2006).
Di Stasi, S. M. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12, 871–879 (2011).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 997–1008 (2011).
Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171, 2186–2190 (2004).
Lammers, R. J. et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur. Urol. 60, 81–93 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
W. Oosterlinck declares he was an invited speaker and received honoraria from Kyowa Hakko Kirin at a conference in Athens, Greece.
Rights and permissions
About this article
Cite this article
Oosterlinck, W. Electromotive mitomycin in superficial bladder cancer. Nat Rev Clin Oncol 8, 633–634 (2011). https://doi.org/10.1038/nrclinonc.2011.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.140
